Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

Jun 13, 2022

SELL
$74.28 - $92.69 $111,420 - $139,035
-1,500 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$71.72 - $91.47 $2.3 Million - $2.93 Million
-32,048 Reduced 95.53%
1,500 $133,000
Q3 2021

Nov 03, 2021

BUY
$74.77 - $85.47 $81,648 - $93,333
1,092 Added 3.36%
33,548 $2.59 Million
Q2 2021

Aug 13, 2021

SELL
$75.51 - $84.79 $32,167 - $36,120
-426 Reduced 1.3%
32,456 $2.71 Million
Q1 2021

May 13, 2021

BUY
$74.73 - $90.69 $549,265 - $666,571
7,350 Added 28.79%
32,882 $2.48 Million
Q4 2020

Feb 08, 2021

SELL
$72.61 - $90.2 $621,033 - $771,480
-8,553 Reduced 25.09%
25,532 $2.24 Million
Q3 2020

Nov 16, 2020

BUY
$71.87 - $131.03 $370,202 - $674,935
5,151 Added 17.8%
34,085 $2.59 Million
Q2 2020

Aug 13, 2020

SELL
$79.55 - $124.22 $819,205 - $1.28 Million
-10,298 Reduced 26.25%
28,934 $3.57 Million
Q1 2020

Apr 14, 2020

SELL
$71.37 - $96.85 $143,310 - $194,474
-2,008 Reduced 4.87%
39,232 $3.32 Million
Q4 2019

Feb 24, 2020

BUY
$64.27 - $86.37 $33,484 - $44,998
521 Added 1.28%
41,240 $3.49 Million
Q3 2019

Oct 29, 2019

BUY
$67.4 - $85.11 $225,992 - $285,373
3,353 Added 8.97%
40,719 $2.74 Million
Q2 2019

Jul 19, 2019

SELL
$80.35 - $93.9 $184,242 - $215,312
-2,293 Reduced 5.78%
37,366 $3.2 Million
Q1 2019

May 09, 2019

BUY
$84.2 - $98.62 $59,276 - $69,428
704 Added 1.81%
39,659 $3.52 Million
Q4 2018

Jan 15, 2019

BUY
$80.14 - $106.07 $75,411 - $99,811
941 Added 2.48%
38,955 $3.32 Million
Q3 2018

Oct 18, 2018

BUY
$93.92 - $105.72 $270,113 - $304,050
2,876 Added 8.18%
38,014 $3.69 Million
Q2 2018

Aug 01, 2018

BUY
$76.01 - $99.03 $31,696 - $41,295
417 Added 1.2%
35,138 $3.31 Million
Q1 2018

Apr 20, 2018

BUY
$77.67 - $92.63 $2.7 Million - $3.22 Million
34,721 New
34,721 $2.82 Million

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $11.5B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Ima Wealth, Inc. Portfolio

Follow Ima Wealth, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ima Wealth, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Ima Wealth, Inc. with notifications on news.